Paget’s Disease - Drug Pipeline Analysis and Market Forecasts to 2016 Digg this page for free send this page to a friend Add to your del.icio.us account

GlobalData’s analysis reveals that the Paget’s disease market was worth $159.2m in 2009. It is forecast to exhibit a negative compound annual growth rate (CAGR) of 8.9% for the next seven years and is expected to reach $82.3m by 2016. The negative growth rate is primarily attributable to a weak pipeline. Furthermore, a substantial decrease in the prevalence of Paget’s disease will lead to a drop in the global prescription population. The market is also predicted to witness generic erosion owing to the patent expiry of products such as Actonel and Fosamax. The market has been steadily declining over the past few years and this trend is likely to continue.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/ Report.aspx?ID=Pagets-disease-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

GlobalData found the current competition in the Paget’s disease market to be strong. Since the market is governed by both branded and generics that fall under the same class of drugs' bisphosphonates ' they have comparable safety and efficacy profiles. This apart, products such as Skelid, which recently lost its patent in 2009, already have generic versions available in the market which are much lower priced than the original molecule. The situation is expected to be repeated again when Actonel and Fosamax lose their respective patent protection. This will certainly lead to a loss in revenues and the market share war in this declining market will become more intense. Also, as no new molecules are likely to enter the market in the next few years and cause a major impact, a negative growth rate is expected until 2016.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/ Report.aspx?ID=Pagets-disease-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

GlobalData found that that the presently available treatment options are moderately successful in meeting patient requirements. Although the drugs that are currently prescribed are primarily used to alleviate symptoms rather than provide a permanent cure to patients, they have been used in patients with Paget’s disease and have yielded beneficial therapeutic outcomes. However, the unmet need in terms of safety and efficacy in this market is low since bisphosphonates are known to cause no major adverse events in patients if the dosing schedule is appropriately adhered to. The clinical unmet need is therefore likely to remain unaltered over the next few years. There is also a possibility that the unmet need may increase as no new drugs are expected to enter the market in the next few years. Reports suggest that the patients are likely to elicit a weaker pharmacological response to drugs upon prolonged exposure. Hence, higher doses, or drugs with more bioavailability will be required to elicit a response in certain groups of patients. Since no new drugs are currently available in the therapeutic pipeline an increase in the clinical unmet need may also be expected.

GlobalData, the industry analysis specialist, has released its new report, “Paget’s Disease ' Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global Paget’s disease market. The report identifies the key trends shaping and driving the market, and provides insight on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Paget’s disease sector.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/ Report.aspx?ID=Pagets-disease-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

Or visit our report store: http://www.globaldata.com/ reportstore
User comments, Ratings and Reviews
News Reviews and Ratings
Be the first person to review this news article. By reviewing the news article you are automatically sent to our Online Sweepstakes and any questions on journal postings and more info from here
News Album Team,  Tuesday, May 21, 2013 8:19:53 AM
Note: To write new journal then start here. The below is only to re-write the existing journal
Write your own Review on This News:

Required valid email. Confirmation sent here.
Not Much. 1 2 3 4 5 So Much......!

Human Verification Code     
Read more! [Bookmark & read later / Comment this story ]
Share this article:

You can Digg this article: Digg this page for free
Send Page to Friend(s):send this page to a friend
Bookmark with del.icio.us:Add to your del.icio.us account

Cast My Opinion

  

Contact Author: Click here to eMail
Rajesh Gunnam from 220.225.231.xxx

Article Taged as : paget’s, disease, drug, pipeline, analysis, market, forecasts, 2016, http, www.globaldata.com, paget’s, disease, drug, pipeline, analysis, market, forecasts, 2016,

Article Statistics

Article Viewed 4346 times.
Positive attitude 1 votes [0%]
Negetive attitude 1 votes [0%]

News Article Source & Groups

You can find this article under group. And brought to you by Channel ,
The XMl Feed Type and collected data bytes sized news and still counting.
Feed Server name is and Code Page (Not Defined/Un Known)

: : Paget’s Disease - Drug Pipeline Analysis and Market Forecasts to 2016
Date Listed : Thursday, March 11, 2010
Source : ,

Related Stories
Home | Topics | Tell a Friend | Webmaster | Events | Subscribe | Link us | Submit News | My List